Insertion of type O-conserved neutralizing epitope into the foot-and-mouth disease virus type Asia1 VP1 G-H loop: effect on viral replication and neutralization phenotype

References

1. Acharya R., Fry E., Stuart D., Fox G., Rowlands D., Brown F. 1989; The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337:709–716 [View Article][PubMed]
   [Google Scholar]
2. Berinstein A., Roivainen M., Hovi T., Mason P. W., Baxt B. 1995; Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 69:2664–2666[PubMed]
   [Google Scholar]
3. Bittle J. L., Houghten R. A., Alexander H., Shinnick T. M., Sutcliffe J. G., Lerner R. A., Rowlands D. J., Brown F. 1982; Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298:30–33 [View Article][PubMed]
   [Google Scholar]
4. Borrego B., Camarero J. A., Mateu M. G., Domingo E. 1995; A highly divergent antigenic site of foot-and-mouth disease virus retains its immunodominance. Viral Immunol 8:11–18 [View Article][PubMed]
   [Google Scholar]
5. Clarke B. E., Newton S. E., Carroll A. R., Francis M. J., Appleyard G., Syred A. D., Highfield P. E., Rowlands D. J., Brown F. 1987; Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330:381–384 [View Article][PubMed]
   [Google Scholar]
6. Dorrell L., Yang H., Iversen A. K., Conlon C., Suttill A., Lancaster M., Dong T., Cebere I., Edwards A.other authors 2005; Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19:1321–1323 [View Article][PubMed]
   [Google Scholar]
7. Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. 1989; An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385–388, 340 [View Article][PubMed]
   [Google Scholar]
8. Fischer D., Rood D., Barrette R. W., Zuwallack A., Kramer E., Brown F., Silbart L. K. 2003; Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge. J Virol 77:7486–7491 [View Article][PubMed]
   [Google Scholar]
9. Fowler V. L., Knowles N. J., Paton D. J., Barnett P. V. 2010; Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion. Vaccine 28:3428–3434 [View Article][PubMed]
   [Google Scholar]
10. Fowler V. L., Bashiruddin J. B., Maree F. F., Mutowembwa P., Bankowski B., Gibson D., Cox S., Knowles N., Barnett P. V. 2011; Foot-and-mouth disease marker vaccine: cattle protection with a partial VP1 G-H loop deleted virus antigen. Vaccine 29:8405–8411 [View Article][PubMed]
    [Google Scholar]
11. Francis M. J., Hastings G. Z., Clarke B. E., Brown A. L., Beddell C. R., Rowlands D. J., Brown F. 1990; Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides. Immunology 69:171–176[PubMed]
    [Google Scholar]
12. Frimann T. H., Barfoed A. M., Aasted B., Kamstrup S. 2007; Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus–importance of dominant and subdominant epitopes for antigenicity and protection. Vaccine 25:6191–6200 [View Article][PubMed]
    [Google Scholar]
13. Grubman M. J., Baxt B. 2004; Foot-and-mouth disease. Clin Microbiol Rev 17:465–493 [View Article][PubMed]
    [Google Scholar]
14. Grubman M. J., Robertson B. H., Morgan D. O., Moore D. M., Dowbenko D. 1984; Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol 50:579–586[PubMed]
    [Google Scholar]
15. Jackson T., Sharma A., Ghazaleh R. A., Blakemore W. E., Ellard F. M., Simmons D. L., Newman J. W., Stuart D. I., King A. M. 1997; Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the purified integrin alpha(v)beta3 in vitro. J Virol 71:8357–8361[PubMed]
    [Google Scholar]
16. Knipe D. M., Howley P. M. 2007; Picornaviridae: the viruses and their replication. In Fields Virology. , 5th edn. pp. 796–830 Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
17. Laird M. E., Desrosiers R. C. 2007; Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops. J Virol 81:10838–10848 [View Article][PubMed]
    [Google Scholar]
18. Logan D., Abu-Ghazaleh R., Blakemore W., Curry S., Jackson T., King A., Lea S., Lewis R., Newman J.other authors 1993; Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362:566–568 [View Article][PubMed]
    [Google Scholar]
19. Lorin C., Delebecque F., Labrousse V., Da Silva L., Lemonnier F., Brahic M., Tangy F. 2005; A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23:4463–4472 [View Article][PubMed]
    [Google Scholar]
20. Mateu M. G., Camarero J. A., Giralt E., Andreu D., Domingo E. 1995; Direct evaluation of the immunodominance of a major antigenic site of foot-and-mouth disease virus in a natural host. Virology 206:298–306 [View Article][PubMed]
    [Google Scholar]
21. McKenna T. S., Lubroth J., Rieder E., Baxt B., Mason P. W. 1995; Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD. J Virol 69:5787–5790[PubMed]
    [Google Scholar]
22. Monaghan P., Gold S., Simpson J., Zhang Z., Weinreb P. H., Violette S. M., Alexandersen S., Jackson T. 2005; The αvβ6 integrin receptor for foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle. J Gen Virol 86:2769–2780 [View Article][PubMed]
    [Google Scholar]
23. Neff S., Sá-Carvalho D., Rieder E., Mason P. W., Blystone S. D., Brown E. J., Baxt B. 1998; Foot-and-mouth disease virus virulent for cattle utilizes the integrin αvβ3 as its receptor. J Virol 72:3587–3594[PubMed]
    [Google Scholar]
24. Pantophlet R., Wang M., Aguilar-Sino R. O., Burton D. R. 2009; The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J Virol 83:1649–1659 [View Article][PubMed]
    [Google Scholar]
25. Pfaff E., Mussgay M., Böhm H. O., Schulz G. E., Schaller H. 1982; Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. EMBO J 1:869–874[PubMed]
    [Google Scholar]
26. Plotkin S. A. 2001; Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20:63–75 [View Article][PubMed]
    [Google Scholar]
27. Reddy K. J., Banapour B., Anderson D. E., Lee S. H., Marquez J. P., Carlos M. P., Torres J. V. 2004; Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. Immunology 112:321–327 [View Article][PubMed]
    [Google Scholar]
28. Rémond M., Da Costa B., Riffault S., Parida S., Breard E., Lebreton F., Zientara S., Delmas B. 2009; Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. Vaccine 27:93–98 [View Article][PubMed]
    [Google Scholar]
29. Ren X., Sodroski J., Yang X. 2005; An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol 79:5616–5624 [View Article][PubMed]
    [Google Scholar]
30. Rieder E., Baxt B., Lubroth J., Mason P. W. 1994; Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol 68:7092–7098[PubMed]
    [Google Scholar]
31. Robertson B. H., Grubman M. J., Weddell G. N., Moore D. M., Welsh J. D., Fischer T., Dowbenko D. J., Yansura D. G., Small B., Kleid D. G. 1985; Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. J Virol 54:651–660[PubMed]
    [Google Scholar]
32. Rong R., Bibollet-Ruche F., Mulenga J., Allen S., Blackwell J. L., Derdeyn C. A. 2007; Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81:1350–1359 [View Article][PubMed]
    [Google Scholar]
33. Rowlands D. J., Clarke B. E., Carroll A. R., Brown F., Nicholson B. H., Bittle J. L., Houghten R. A., Lerner R. A. 1983; Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature 306:694–697 [View Article][PubMed]
    [Google Scholar]
34. Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. 1997; Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A 94:7503–7508 [View Article][PubMed]
    [Google Scholar]
35. Varsani A., Williamson A. L., de Villiers D., Becker I., Christensen N. D., Rybicki E. P. 2003; Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77:8386–8393 [View Article][PubMed]
    [Google Scholar]
36. Wang H., Zhao L., Li W., Zhou G., Yu L. 2011; Identification of a conformational epitope on the VP1 G-H Loop of type Asia1 foot-and-mouth disease virus defined by a protective monoclonal antibody. Vet Microbiol 148:189–199 [View Article][PubMed]
    [Google Scholar]
37. Yang C. D., Liao J. T., Lai C. Y., Jong M. H., Liang C. M., Lin Y. L., Lin N. S., Hsu Y. H., Liang S. M. 2007; Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes. BMC Biotechnol 7:62 [View Article][PubMed]
    [Google Scholar]
38. Yang D., Zhang C., Zhao L., Zhou G., Wang H., Yu L. 2011; Identification of a conserved linear epitope on the VP1 protein of serotype O foot-and-mouth disease virus by neutralising monoclonal antibody 8E8. Virus Res 155:291–299 [View Article][PubMed]
    [Google Scholar]
39. Yu Y., Wang H., Zhao L., Zhang C., Jiang Z., Yu L. 2011; Fine mapping of a foot-and-mouth disease virus epitope recognized by serotype-independent monoclonal antibody 4B2. J Microbiol 49:94–101 [View Article][PubMed]
    [Google Scholar]
40. Zhao Y., Hammond R. W. 2005; Development of a candidate vaccine for Newcastle disease virus by epitope display in the cucumber mosaic virus capsid protein. Biotechnol Lett 27:375–382 [View Article][PubMed]
    [Google Scholar]